Caring Healthcare has been awarded the "2022 Future Medical Top 100 • Top 10 Value Areas List - TOP10 in Life Science Tools and Services"

Recently, the 8th VBEF Future Medical Ecology Exhibition Awards Ceremony, hosted by VB100, Arterial Network, Eggshell Research Institute, and Arterial Orange, was grandly held in Beijing, officially announcing the results of the 2024 Future Medical Top 100 selection. Caring Healthcare has been listed as one of the top 100 companies in the future healthcare industry in 2024, and has been honored as one of the "Top 100 Service Providers in the Future Healthcare China Healthcare Industry Chain".

The Future Medical Top 100 list, founded in 2015, is the first innovative medical field list for non listed enterprises in China launched by VB100, Arterial Network, and Eggshell Research Institute. Its aim is to select Chinese innovative medical professionals who truly represent future medical care, discover the core strength of China's future medical industry, and promote the innovation and transformation process of the health and medical industry. After 8 years of practice and exploration, the "Future Medical Top 100 Selection" has received strong support and recognition from numerous investment institutions and enterprises, and has become an investment benchmark in the medical and health field, leading the development and investment direction of China's medical and health innovation field in the current and future period, and providing reference and guidance for innovative enterprises' subsequent financing.

This ranking is open to non listed companies in the healthcare industry. Based on the VB100 value evaluation model, through the process of independent application by enterprises, VB100 review by the evaluation committee, cross evaluation by supporting institutions, and final review by the expert committee, the top 100 innovative enterprises with valuation rankings are selected from the four major fields (innovative devices and intelligent manufacturing/innovative pharmaceuticals and biological products/medical and health innovation services/medical and health industry chain services). In addition to valuation, the growth and annual performance of candidate companies in four primary indicators: human resources, knowledge resources, important partner resources, and market performance, totaling 17 secondary indicator data, will be further examined.